Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex Hopes To PROVE Telaprevir’s Promise With Final Installment Of Phase II Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Company plans to begin Phase III in the second half of 2007; further protocol discussions with FDA are planned for mid-2007.
Advertisement

Related Content

Vertex Telaprevir NDA In Treatment-Naïve Hep C Now Planned For 2010
Interim Phase II Telaprevir Data Point To Possible Shortened Hep C Treatment Course
Novartis/Human Genome Sciences Launch Second Phase III Albuferon Trial
BIO Panel: Polymerase, Protease Inhibitor Combinations On The Horizon For Hepatitis C
Gilead/Achillion Advance Back-Up Anti-HCV Molecule After Toxicity Problems With Lead Candidate
GSK Halts Development Of Vertex’ Brecanavir Due To Formulation Concerns
J&J/Vertex HCV Protease Inhibitor Results Tempered By Higher Adverse Events
J&J/Vertex HCV Protease Inhibitor Results Tempered By Higher Adverse Events
Schering-Plough Takes The Long Road To Early Stage Hep C R&D
J&J, Vertex Partner To Commercialize VX-950 For Hepatitis C

Topics

Advertisement
UsernamePublicRestriction

Register

PS065652

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel